secwatch.observer — SEC 8-K summary
======================================

Issuer:     INFINITY PHARMACEUTICALS, INC. (—)
CIK:        0001113148
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001140361-23-032462
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Infinity Pharma receives Nasdaq delisting notice for bid price noncompliance; plans appeal
--------------------------------------------------------------------------------

- Nasdaq Staff determined to delist INFI for failure to regain compliance with minimum $1.00 bid price within 180-day period that began Dec 28, 2022.
- Delisting scheduled for July 7, 2023 unless Company requests hearing by July 5, 2023; Company intends to request hearing.
- Company also remains out of compliance with Nasdaq's market value of listed securities rule (minimum $50M) with grace period expiring October 2, 2023.
- Hearing Panel can grant extension through December 26, 2023; no guarantee of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1113148/000114036123032462/0001140361-23-032462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1113148/000114036123032462/brhc20055271_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-032462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer